At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 103 enrolled
Drug / intervention
Duvelisibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Open-label, 2-Arm Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Subjects With Indolent Non-Hodgkin Lymphoma (iNHL)
In Brief
A Phase 2 clinical trial evaluating Duvelisib for Indolent Non-Hodgkin Lymphoma. Completed, enrolled 103 participants across 28 sites in 8 countries.
Detailed Summary
This study examined the effects of predefined 2-week duvelisib dose holidays on tumor responses and safety/tolerability.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIndolent Non-Hodgkin Lymphoma
CountriesCzechia, Germany, Italy, Poland, Russia, South Korea, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedJul 2019
Enrollment StartSep 2019
Primary CompletionJul 2023
TodayJul 2026
First PostedJul 30, 2019
Enrollment StartSep 24, 2019
Primary CompletionJul 24, 2023
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 6.9 years ago
Interventions
Duvelisibdrug
Phosphoinositide 3-kinase (PI3K) inhibitor